Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus

被引：18

作者：

Dannaoui, E. ^{[1
]}

Garcia-Hermoso, D.

Naccache, J. M.

Meneau, I.

Sanglard, D.

Bouges-Michel, C.

Valeyre, D.

Lortholary, O.

机构：

[1] Inst Pasteur, Ctr Natl Reference Mycol & Antifong, Unite Mycol Mol, CNRS,FRE2849, F-75724 Paris 15, France

[2] Univ Paris Descartes, Fac Med, AP HP, Hop European Georges Pompidou,Unite Parasitol Myc, F-75015 Paris, France

[3] Hop Avicenne, Serv Pneumol, F-93009 Bobigny, France

[4] Univ Hosp Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland

[5] Hop Avicenne, Lab Parasitol Mycol, F-93009 Bobigny, France

[6] Univ Paris Descartes, Fac Med, Hop Necker Enfants Malad, AP HP,Serv Malad Infect & Trop, F-75743 Paris 15, France

来源：

JOURNAL OF MEDICAL MICROBIOLOGY | 2006年 / 55卷 / 10期

关键词：

D O I：

10.1099/jmm.0.46639-0

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The case is reported of a patient with cavitary sarcoidosis complicated by an aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus, who was treated with voriconazole. The authors suggest that susceptibility testing of A. fumigatus strains is of value during long-term therapy with itraconazole, and that voriconazole may be a good option for treatment of patients infected with itraconazole-resistant strains of A. fumigatus.

引用

页码：1457 / 1459

页数：3

共 14 条

[1] In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole
Chryssanthou, E
[J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1997, 29 (05) : 509 - 512
[2] Acquired itraconazole resistance in Aspergillus fumigatus
Dannaoui, E
Borel, E
Monier, MF
Piens, MA
Picot, S
Persat, F
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) : 333 - 340
[3] Itraconazole resistance in Aspergillus fumigatus
Denning, DW
Venkateswarlu, K
Oakley, KL
Anderson, MJ
Manning, NJ
Stevens, DA
Warnock, DW
Kelly, SL
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1364 - 1368
[4] Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation
Espinel-Ingroff, A
Bartlett, M
Chaturvedi, V
Ghannoum, M
Hazen, KC
Pfaller, MA
Rinaldi, M
Walsh, TJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) : 1828 - 1835
[5] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Herbrecht, R
Denning, DW
Patterson, TF
Bennett, JE
Greene, RE
Oestmann, JW
Kern, WV
Marr, KA
Ribaud, P
Lortholary, O
Sylvester, R
Rubin, RH
Wingard, JR
Stark, P
Durand, C
Caillot, D
Thiel, E
Chandrasekar, PH
Hodges, MR
Schlamm, HT
Troke, PF
de Pauw, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415
[6] Substitutions at methionine 220 in the 14α-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs
Mellado, E
Garcia-Effron, G
Alcazar-Fuoli, L
Cuenca-Estrella, M
Rodriguez-Tudela, JL
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) : 2747 - 2750
[7] Azole cross-resistance in Aspergillus fumigatus
Mosquera, J
Denning, DW
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (02) : 556 - 557
[8] Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate
Slaven, JW
Anderson, MJ
Sanglard, D
Dixon, GK
Bille, J
Roberts, IS
Denning, DW
[J]. FUNGAL GENETICS AND BIOLOGY, 2002, 36 (03) : 199 - 206
[9] The clinical spectrum of pulmonary aspergillosis
Soubani, AO
Chandrasekar, PH
[J]. CHEST, 2002, 121 (06) : 1988 - 1999
[10] Practice guidelines for diseases caused by Aspergillus
Stevens, DA
Kan, VL
Judson, MA
Morrison, VA
Dummer, S
Denning, DW
Bennett, JE
Walsh, TJ
Patterson, TF
Pankey, GA
[J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) : 696 - 709

← 1 2 →